Jonathan Piccini, MD, MHS discusses evaluating superiority vs non-inferiority in clinical trials, as reported in Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Günter Breithardt, M.D., Jonathan L. Halperin, M.D., Graeme J. Hankey, M.D., Jonathan P. Piccini, M.D., Richard C. Becker, M.D., Christopher C. Nessel, M.D., John F. Paolini, M.D., Ph.D., Scott D. Berkowitz, M.D., Keith A.A. Fox, M.B., Ch.B., Robert M. Califf, M.D., and the ROCKET AF Steering Committee for the ROCKET AF Investigators
Dr. Piccini receives research funding to the DCRI from Bayer Healthcare, Johnson & Johnson, and Boston Scientific, and consultancy fees from Sanofi-Aventis, CE Outcomes. Dr. Piccini was an investigator in ROCKET AF.
Please refer to the full text article for all disclosures.
